Mylan gets generic Copaxone nod from FDA

Netherlands-incorporated drugmaker Mylan has received approval from the US Food and Drug Administration for its generic version of Copaxone (glatiramer acetate) at 40 mg/mL for a three-times-a-week injection, and the once daily 20 mg/mL injection.

Copaxone, which is marketed by Teva Pharmaceutical Industries, is indicated for the treatment of patients with relapsing forms of multiple sclerosis.